PainReform Ltd. (NASDAQ:PRFX) Short Interest Down 76.0% in November

PainReform Ltd. (NASDAQ:PRFX) was the target of a large decline in short interest in November. As of November 15th, there was short interest totalling 29,100 shares, a decline of 76.0% from the October 31st total of 121,100 shares. Based on an average trading volume of 904,100 shares, the days-to-cover ratio is currently 0.0 days. Currently, 5.2% of the company’s stock are short sold.

PainReform Trading Up 1.1 %

PainReform stock traded up $0.03 during trading hours on Thursday, hitting $2.75. 181,674 shares of the stock traded hands, compared to its average volume of 268,438. The firm’s 50-day moving average price is $2.60 and its two-hundred day moving average price is $2.28. The company has a market cap of $398,750.00, a PE ratio of -0.02 and a beta of 0.56. PainReform has a one year low of $1.73 and a one year high of $80.64.

Analyst Upgrades and Downgrades

Separately, Maxim Group reaffirmed a “hold” rating on shares of PainReform in a research report on Thursday, October 24th.

Institutional Trading of PainReform

An institutional investor recently raised its position in PainReform stock. Armistice Capital LLC raised its position in shares of PainReform Ltd. (NASDAQ:PRFX) by 76.9% during the 2nd quarter, according to the company in its most recent 13F filing with the SEC. The institutional investor owned 276,000 shares of the company’s stock after acquiring an additional 120,000 shares during the quarter. Armistice Capital LLC owned approximately 13.60% of PainReform worth $132,000 at the end of the most recent quarter. Hedge funds and other institutional investors own 37.28% of the company’s stock.

About PainReform

PainReform Ltd., a clinical stage specialty pharmaceutical company, focuses on the reformulation of established therapeutics and provides an extended period of post-surgical pain relief in Israel. It develops PRF-110, a viscous clear oil-based solution that is instilled directly into the surgical wound to provide localized and extended post-operative analgesia, as well as in Phase 3 clinical trial for pain treatment of patients undergoing bunionectomy and second trial for pain treatment of hernia repair operations.